The Pharmacy Times® Pharmacy Hospital Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to hospital and health-system pharmacists.
July 16th 2025
Since the most recent guidelines were published, more evidence has emerged regarding intravenous corticosteroids for severely ill patients.
Expert: Cancer Screening Rates in 2021 Remain Lower Than Expected
February 2nd 2022Christopher Mast, MD, vice president of clinical informatics at Epic, discusses research that showed that cancer screening rates in 2021 rebounded from the low rates at the start of the pandemic, but not significantly.
Watch
Study: People Living With HIV Need Custom COVID-19 Vaccination Information
February 2nd 2022Although COVID-19 vaccination rates have increased since the survey was initially conducted, the researchers noted that their results are important when considering the possibility of an annual COVID-19 vaccine.
Read More
ASHP Discusses Grant Received From American Rescue Plan
January 28th 2022Anna Legreid Dopp, PharmD, the Senior Director of Clinical Guidelines & Quality Improvement at ASHP, and Bayli Larson, PharmD, the Strategic Initiatives Associate at ASHP, discuss the grant the ASHP received from the American Rescue Plan.
Watch
Pharmacist Medication Insights: Abemaciclib (Verzenio) for Breast Cancer
January 28th 2022Abemaciclib (Verzenio) was recently approved in combination with endocrine therapy for the adjuvant treatment of adult patients with HR–positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence.
Watch
Is a 90-Day Supply the Best Option to Improve Medication Adherence?
Interventions to improve medication adherence may have a greater impact on individual patients and the population as a whole than any novel treatment or therapy.
Read More
Pfizer, BioNTech to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 27th 2022The study will have 3 cohorts examining different regimens of the current Pfizer-BioNTech COVID-19 vaccine or an omicron-based vaccine and will use participants from the phase 3 COVID-19 booster study.
Read More